GlassScriptPhysician profile
Thaddeus Y Carson
NPI 1750602967
$1,286.06
in general payments reported to CMS, 2019-2025
19 companies · $63.05 in 2025
The $63.05 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.25 · 2020: $82.13 · 2021: $176 · 2022: $302 · 2023: $327 · 2024: $294 · 2025: $63.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.08 | 2021-2024 | Teflaro, Dalvance, Avycaz |
| Pfizer INC. | $183.67 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $172.38 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $125.84 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $75.84 | 2023-2024 | Inpefa |
| Amgen INC. | $65.08 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.27 | 2021-2025 | Eliquis |
| Aurinia Pharma U.S., INC. | $44.81 | 2022-2024 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $42.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.10 | 2022-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $36.44 | 2022 | |
| Radius Health, INC. | $31.68 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.38 | 2022 | |
| Ibsa Pharma INC. | $17.19 | 2024 | Tirosint, Licart |
| Alexion Pharmaceuticals, INC. | $16.98 | 2023 | Ultomiris |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.70 | 2019 | |
| Merck Sharp & Dohme LLC | $15.06 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Mylan Specialty L.P. | $11.77 | 2022 | |
| Shire North American Group INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeus Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.